ISOgenix

ISOgenix is a biotechnology company developing precision medicines that target disease-relevant protein isoforms for neuromuscular and neurological conditions.

The company's approach focuses on identifying and modulating specific isoforms produced through alternative gene splicing and epigenetic regulation, aiming to restore normal protein function in genetic motor unit disorders such as spinal and bulbar muscular atrophy.

ISOgenix is a University of Oxford spin-out, backed by Oxford Science Enterprises.